Pulmonary Nodules
Conditions
Interventions
Group O1:Intravenous injection of 1mg/ml oxycodone hydrochloride injection 0.025mg/kg.
Group O2:Intravenous injection of 1mg/ml oxycodone hydrochloride injection 0.05mg/kg.
Group O3:Intravenous injection of 1mg/ml oxycodone hydrochloride injection 0.075mg/kg.
Group O4:Intravenous injection of 1mg/ml oxycodone hydrochloride injection 0.1 mg/kg.
Group C:Intravenous injection of an equal amount of 0.9% sodium chloride solution.
Sponsors
Jiangsu Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-64 years who intend to undergo Computer Tomography (CT) -guided localization of pulmonary nodules with microcoil; 2. American Society of Anesthesiologists (ASA) Grades II-III; 3. Subjects voluntarily participate in this study and have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Cognitive or communication difficulties; 2. People with severe lung disease or dysfunction (chronic obstructive pulmonary disease, COPD, chronic Bronchial asthma, hypercapnia, pulmonary tuberculosis, moderate pulmonary hypertension, etc.); 3. Patients with severe cardiovascular disease caused by hemodynamic instability (hypertension control is ignored Such as systolic blood pressure =180mmHg or diastolic blood pressure =110mmHg, arrhythmia, valvular heart disease, Pulmonary heart disease, cardiac dysfunction and inability to lie flat, myocardial infarction within 6 months); 4. Moderate or above liver function impairment (aminotransferase or bilirubin value increased by more than 2 times, liver Sclerotic, decompensated liver disease, active hepatitis or chronic hepatitis requiring antiviral therapy); 5. Patients with severe renal impairment requiring hemodialysis or peritoneal dialysis; 6. Patients with a history of pulmonary surgery; 7. Patients with multiple pulmonary nodules requiring multiple location at one time; 8. Chronic constipation; 9. Recent use of cough medicines, psychotropic drugs or analgesics; 10. Recent drinkers; 11. Arterial/venous thrombosis events such as cerebral infarction, pulmonary embolism and deep vein thrombosis occurred within 6 months; 12. People who are taking anticoagulant drugs or have coagulation disorders; 13. Allergic to oxycodone or other test equipment, have a history of severe drug allergy, and have severe allergy This; 14. There are any other contraindications to the use of oxycodone; 15. The researcher considers that there are other circumstances that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Nnalogue Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vital signs in peri-puncture;The incidence of irritant symptoms during puncture (respiratory incoordination, cough, movement of body);The incidence of complications of puncture (pneumothorax, pulmonary hemorrhage, pleural reaction);The incidence of adverse drug reactions (respiratory depression, dizziness, nausea and vomiting); | — |
Countries
China
Contacts
Public ContactWang Lijun
Jiangsu Cancer Hospital
Outcome results
None listed